In a new article, experts from Medpace’s radiation oncology, imaging, regulatory, and operational teams discuss the growing space of radiopharmaceutical development.
Read More
Medpace is pleased to announce that Dr. Blythe Thomson has rejoined Medpace’s Hematology and Oncology medical leadership team after spending several years holding a variety of Executive Medical Director level roles in the pharmaceutical industry.
Read More
Medpace Core Laboratories successfully completed a comprehensive inspection by the FDA on a late phase, registrational, oncology trial. The inspection concluded with no major or minor findings, reflecting the high quality and systematic execution of the trial by MCL.
Read More
An in-depth look at infectious diseases including hematologic malignancies in immunocompromised patients and the unique challenges for clinical development.
Read More
As more agents approach the clinic, it is imperative for researchers to consider the design and conduct of immuno-oncology clinical trials. Given the diversity of agents in this newly tapped field, researchers may encounter unique challenges for site selection, patient selection, biomarker selection and imaging for assessing patient responses.
Read More
Several weeks ago, we announced that Dr. Gregory Hale joined the Medpace medical leadership team. He is an experienced physician with clinical expertise in bone marrow transplantation, cellular therapies, and hematologic malignancies. We were eager to sit down with Dr. Hale to learn more about what attracted him to the Medpace model and what new innovations he is most excited about.
Read More